anmelden
Here's What I Think Is Really Going on With Novo Nordisk Stock
Werte in diesem Artikel
The market for chronic weight management drugs has grown significantly in recent years. Analysts project that this trend will continue into the next decade. Novo Nordisk (NYSE: NVO) is one of the undisputed leaders in this niche, so one might think the company has performed well -- and will continue to do so -- as it rides this tailwind. However, over the past two years, Novo Nordisk's shares have lost about 68% of their value. What is going on with the Denmark-based pharmaceutical giant? Let's find out. Image source: The Motley Fool.Clinical and regulatory wins are important catalysts for pharmaceutical companies. In fact, these often drive the stock price just as much as financial results. The market rewarded Novo Nordisk for its work in the anti-obesity market, as the company launched its now-famous medicine, Wegovy, whose sales were once growing incredibly rapidly. Wegovy became so popular that it even encountered shortages.Continue readingWeiter zum vollständigen Artikel bei MotleyFool
Ausgewählte Hebelprodukte auf Going
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Going
Der Hebel muss zwischen 2 und 20 liegen
| Name | Hebel | KO | Emittent |
|---|
| Name | Hebel | KO | Emittent |
|---|
Quelle: MotleyFool
